CNTA
HealthcareCentessa Pharmaceuticals plc · Biotechnology · $6B
What is Centessa Pharmaceuticals plc?
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing medicines across rare and serious diseases. It operates a diversified pipeline spanning multiple therapeutic areas.
Centessa advances drug candidates through clinical trials, generating no product revenue at this stage. Its business model centers on progressing pipeline assets toward regulatory approval and potential commercialization or partnership. The company funds operations through capital markets rather than product sales.
Founded in 2021 and headquartered in Altrincham, UK.
- Lixivaptan – Phase III candidate for autosomal dominant polycystic kidney disease
- SerpinPC – Phase IIa inhibitor for hemophilia A and B
- ZF874 – Phase I small molecule for alpha-1-antitrypsin deficiency
- OX2R Agonists – oral and intranasal candidates targeting Narcolepsy Type 1
Is CNTA a Good Stock to Buy?
UQS Score rates CNTA as Poor overall, reflecting the early-stage nature of its business.
The Growth and Risk pillars stand out as relative positives, consistent with a pipeline company advancing multiple candidates. These labels suggest the company's development trajectory and risk profile compare reasonably within the clinical-stage peer group.
Quality and Moat are both rated Weak, which is typical for pre-revenue biotechs lacking established earnings power or durable competitive advantages. Valuation is rated Elevated.
See the full pillar breakdown and financial metrics by signing up for a Pro account at uqs-score.com. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CNTA pay dividends?
No — Centessa Pharmaceuticals plc does not currently pay a dividend.
Centessa does not pay a dividend. As a clinical-stage company with no product revenue, available capital is directed toward advancing its pipeline through clinical trials rather than returning cash to shareholders.
When does CNTA report earnings?
Centessa Pharmaceuticals reports on a quarterly cadence, typical for US-listed equities.
As a pre-revenue company, quarterly reports focus on pipeline progress, cash runway, and operating expenses rather than sales or profit metrics. Clinical trial readouts tend to be more market-moving than earnings beats or misses.
For the most recent results and pipeline updates, visit Centessa Pharmaceuticals' investor relations page.
CNTA Price History
+81.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Centessa Pharmaceuticals plc?
Based on Centessa Pharmaceuticals plc's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Centessa Pharmaceuticals do?
Centessa is a clinical-stage pharmaceutical company developing medicines for rare and serious diseases. Its pipeline includes candidates for polycystic kidney disease, hemophilia, alpha-1-antitrypsin deficiency, and narcolepsy, among others. The company has not yet commercialized any products.
Does CNTA pay dividends?
No, CNTA does not pay a dividend. Clinical-stage biotechs typically reinvest all available capital into research and development rather than distributing cash to shareholders.
When does CNTA report earnings?
Centessa reports on a quarterly basis. Because it is pre-revenue, pipeline milestones and cash position updates are often more significant than the earnings figures themselves. Check the company's investor relations page for the current schedule.
Is CNTA a good stock to buy?
UQS Score rates CNTA as Poor overall. While Growth and Risk pillars show relative strength, Quality and Moat are Weak and Valuation is Elevated. The complete pillar analysis is available to Pro members at uqs-score.com.
Is CNTA overvalued?
The UQS Valuation pillar for CNTA is rated Elevated, suggesting the market is pricing in significant future success relative to current fundamentals. This is common for clinical-stage biotechs where value depends on pipeline outcomes.
What is CNTA's market cap bracket?
Centessa Pharmaceuticals is classified as a mid-cap company based on current market capitalization.
Is CNTA a long-term quality investment?
From a quality standpoint, CNTA's UQS profile shows Weak scores on Quality and Moat pillars, which are key long-term durability indicators. Pipeline success could change this profile materially, but current fundamentals reflect early-stage risk. Pro members can view the full analysis.
What sector does CNTA belong to?
Centessa Pharmaceuticals operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Investors can explore other [healthcare stocks scored by UQS](/sector/healthcare) for sector-wide comparisons.
Unlock Full CNTA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete 5-pillar UQS Score breakdown for CNTA
- ✓Access detailed financial metrics and quality indicators
- ✓Compare CNTA against clinical-stage peers side by side
- ✓Track pipeline-stage companies across the Healthcare sector
Pro Analysis
CNTA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 24.5 | 0.8 | 10.0 | 53.7 | 73.3 | 0.0 | +0.3 |
| May 10, 2026 | 24.2 | 0.0 | 10.0 | 53.7 | 73.3 | 0.0 | -0.2 |
| Apr 22, 2026 | 24.4 | 0.8 | 10.0 | 53.7 | 72.8 | 0.0 | -2.7 |
| Apr 2, 2026 | 27.1 | 0.8 | 10.0 | 67.2 | 72.8 | 0.0 | — |
CNTA — Pillar Breakdown
Quality
— 0.8/100 (25%)Centessa Pharmaceuticals plc currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 53.7/100 (20%)Centessa Pharmaceuticals plc shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 73.3/100 (15%)Centessa Pharmaceuticals plc maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Centessa Pharmaceuticals plc appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 10/100 (25%)Centessa Pharmaceuticals plc operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CNTA.
Score Composition
Financial Data
More Stock Analysis
How is the CNTA UQS Score Calculated?
The UQS (Unified Quality Score) for Centessa Pharmaceuticals plc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Centessa Pharmaceuticals plc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Centessa Pharmaceuticals plc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.